Showing results (11-20 of 206) with videos related to
Sort By:
Pageof 21
Drug and Alcohol Dependence|October 21, 2015
States' implementation of the Affordable Care Act and the supply of physicians waivered to prescribe buprenorphine for opioid dependenceHannah K Knudsen, Michelle R Lofwall, Jennifer R Havens, et al.Addictive Behaviors|January 29, 2019
Perceived need and availability of psychosocial interventions across buprenorphine prescriber specialtiesLewei Allison Lin, Michelle R Lofwall, Sharon L Walsh, et al.Preventive Medicine|June 29, 2019
Integrated outpatient treatment of opioid use disorder and injection-related infections: A description of a new care modelLaura C Fanucchi, Sharon L Walsh, Alice C Thornton, et al.The International Journal on Drug Policy|May 5, 2019
Impact of health reform on health insurance status among persons who use opioids in eastern Kentucky: A prospective cohort analysisHannah K Knudsen, Michelle R Lofwall, Sharon L Walsh, et al.Journal of Substance Abuse Treatment|June 14, 2011
Efficacy of continuing medical education to reduce the risk of buprenorphine diversionMichelle R Lofwall, Martha J Wunsch, Paul A Nuzzo, et al.Drug and Alcohol Dependence|July 9, 2008
The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusersSharon L Walsh, Paul A Nuzzo, Michelle R Lofwall, et al.Drug and Alcohol Dependence|March 26, 2016
Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusersSharon L Walsh, Paul A Nuzzo, Shanna Babalonis, et al.Journal of Addiction Medicine|December 4, 2024
Exploring Opioid Use Disorder Outcomes by Quantitative Urinalysis: Post Hoc Analysis of a Phase 3 Randomized Clinical TrialStefan Peterson, Edward V Nunes, Michelle R Lofwall, et al.Addiction Biology|January 21, 2012
Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusersSharon L Walsh, Markus Heilig, Paul A Nuzzo, et al.Psychopharmacology|May 14, 2021
Evaluation of tradipitant, a selective NK1 antagonist, on response to oxycodone in humansMarion A Coe, Michelle R Lofwall, Victoria Vessels, et al.Pageof 21